VALCHLOR® (mechlorethamine) gel is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides–type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy

A treatment for
Stage IA/IB MF-CTCL that is clear

Artistic rendition of Stage IA/IB MF-CTCL. Not an actual patient.

*VALCHLOR (n=119) was assessed in a 12-month randomized, multicenter, observer-blinded, noninferiority study trial (N=260) vs Aquaphor®-based mechlorethamine HCl 0.02%. Primary endpoint: response by CAILS (Composite Assessment of Index Lesion Severity) score (combined scores for erythema, scaling, plaque elevation, and surface area). CAILS ORR: 60% (PR 45% + CR 14%). VALCHLOR noninferiority demonstrated by the rate ratio of 1.24 (95% CI, 0.98, 1.58). ORR (overall response rate) = PR (partial response) + CR (complete response, defined as a score of 0).1

VALCHLOR is the first and only FDA-approved
topical form of mechlorethamine1,2

The VALCHLOR copay program is only available for US and Puerto Rico residents who are 18 or older and have commercial health insurance with copay/coinsurance exceeding $10 $0 per prescription fill. Patients ineligible for the VALCHLOR copay program include those enrolled in Medicare, Medicaid, VA/DoD (Tricare), the Indian Health Service, or any other federal- or state-funded healthcare program, or where prohibited by law. The VALCHLOR copay program is not prescription drug coverage or insurance. Helsinn Therapeutics, Inc. reserves the right to terminate or modify this program at any time or without notice. Other terms and conditions apply.